BioMarin Pharmaceutical (NASDAQ:BMRN) Announces Quarterly Earnings Results

BioMarin Pharmaceutical (NASDAQ:BMRN) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.18, Zacks reports. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. BioMarin Pharmaceutical updated its FY 2025 guidance to 4.200-4.400 EPS.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock opened at $65.61 on Thursday. The firm has a market cap of $12.50 billion, a price-to-earnings ratio of 39.29, a price-to-earnings-growth ratio of 0.57 and a beta of 0.28. The stock’s 50-day moving average is $64.79 and its 200-day moving average is $71.10. BioMarin Pharmaceutical has a one year low of $60.63 and a one year high of $94.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on BMRN shares. Wolfe Research started coverage on BioMarin Pharmaceutical in a research report on Friday, November 15th. They issued an “outperform” rating and a $95.00 price objective for the company. Wedbush upgraded BioMarin Pharmaceutical to a “strong-buy” rating in a research report on Monday, November 4th. UBS Group lifted their price objective on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Citigroup lowered their target price on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. Finally, William Blair cut BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $94.20.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.